Research Article
Postintravitreal Injection Endophthalmitis: Incidence, Characteristics, Management, and Outcome
Table 1
Intravitreal injections rate and the endophthalmitis rate in two medical centers during the study period.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
() = 0.025 for steroidal agents in comparison to anti-VEGF agents; = 0.037 for bevacizumab in comparison to ranibizumab; = 0.09 for aflibercept in comparison to ranibizumab; = 0.437 for aflibercept in comparison to bevacizumab; = 0.164 for triamcinolone acetonide injectable suspension in comparison to dexamethasone intravitreal implant. |